Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | CMA1 | P23946 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075234 | 1.00 | VHL (0.45) | VHLMC4RMC5ROPRM1OPRD1 | |
| SCHEMBL2075581 | 0.88 | VHL (0.50) | VHLOPRM1OPRD1OPRK1XIAP | |
| SCHEMBL2075346 | 0.84 | VHL (0.49) | VHLMC4RMC5ROPRM1OPRD1 | |
| SCHEMBL2075347 | 0.84 | VHL (0.49) | VHLMC4RMC5ROPRM1OPRD1 | |
| SCHEMBL2296377 | 0.82 | VHL (0.46) | VHLOPRM1OPRD1OPRK1XIAP | |
| SCHEMBL749563 | 0.82 | USP30 (0.51) | VHLOPRM1OPRD1OPRK1NPC1 | |
| SCHEMBL2074631 | 0.81 | VHL (0.53) | VHLOPRM1OPRD1OPRK1XIAP | |
| SCHEMBL2074630 | 0.81 | VHL (0.53) | VHLOPRM1OPRD1OPRK1XIAP | |
| SCHEMBL3660929 | 0.81 | CYP3A4 (0.45) | VHLLMNA | |
| SCHEMBL16932339 | 0.80 | USP30 (0.43) | USP30F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| EP-2231597-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009074829-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | VHL 4069/4885MC4R 796/4885MC5R 506/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | VHL 4069/4885MC4R 796/4885MC5R 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.